EctoPharma
  • Home
  • ABOUT US
    • The Company – What we do
    • Business Model
    • Current Work
    • Who’s Who
    • In the Media
      • December 2010
      • September 2010
      • June 2010
      • December 2009
  • OUR PRODUCTS
    • KindaPed™
      • UK Launch of “Hedrin Treat & Go”
      • Properties of KindaPed™
      • Current Lice Treatments
      • Efficacy
      • Market Size
    • Ryboquin™
      • The Background
      • The Process
      • Why Pancreatic Cancer?
  • SHAREHOLDERS
    • Presentations
    • Letters
  • Contact us

Why Pancreatic Cancer?

  • Pancreatic cancer is the tenth most common cancer in the UK.
  • Approximately 7,500 new cases each year – 3% of all cancers.
  • 80% of cases occur in people aged 60 and over.
  • Typical post diagnosis survival period short.
  • If effective in pancreatic cancer, this would be excellent “proof of principle” for larger cancer indications.

 

 

Comments are closed.



Ryboquin™

  • The Background
  • The Process
  • Why Pancreatic Cancer?
Go To Top »

Copyright Ectopharma 2011